Overview

• Regencell’s shares have climbed over 46,000% this year, lifting its market capitalization to approximately $36 billion
• A single trading session after the split saw shares jump 280% and triggered more than ten volatility halts
• CEO Yat-Gai Au controls about 86% of the company’s shares, a stake valued at roughly $25 billion
• The company is developing natural TCM formulas for ADHD and autism and posted a $4.4 million net loss in the fiscal year ending June 2024
• Analysts have cautioned that Regencell’s tiny 6% public float and absence of commercial revenue make its stock exceptionally volatile